Skip to main content

Becton Dickinson and Company(BDX-N)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

BD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients with Treatments

PR Newswire - Tue Aug 9, 5:50AM CDT

Companies combine key capabilities to advance flow cytometry as an essential companion diagnostic modality for cancer and other diseases

FRANKLIN LAKES, N.J., Aug. 9, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp (NYSE: LH), a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.


Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.